Made in the USA · Third-Party Tested

Metabolic Research Compound

Retatrutide

Retatrutide LY3437943 GLP-1/GIP/Glucagon Triple Agonist

Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical data showed significant weight loss in human subjects. Sold strictly for research purposes only.

Dosage

★ Best Seller

Purchase Options

Quantity

$160.00

Bundle & Save

1 Bottle

Certificate of Analysis

Full-panel third-party testing on every batch. 8× independent QC checks before any vial ships.

99.83%

Purity (HPLC-UV) · Identity Confirmed

Full panel passed

Retatrutide · 5mg

Lot 261807 · Freedom Diagnostics
Reported Jul 24, 2026

View Certificate

99.95%

Purity (HPLC-UV) · Identity Confirmed

Full panel passed

Retatrutide · 10mg

Lot 261807 · Freedom Diagnostics
Reported Jul 24, 2026

View Certificate

99.86%

Purity (HPLC-UV) · Identity Confirmed

Full panel passed

Retatrutide · 30mg

Lot 261807 · Freedom Diagnostics
Reported Jul 24, 2026

View Certificate

8× Full QC Panel

Purity (HPLC) · Net Peptide Content · Identity (HPLC) · Fentanyl Screen · HPLC Conformity · Heavy Metals (ICP-MS) · Sterility (PCR) · Endotoxin (USP <85>)

All tests · Every batch

Compound Information

Technical specifications

What Is Retatrutide?

Molecular Profile

Type	GLP-1/GIP/Glucagon receptor tri-agonist
CAS Number	2381524-05-4
Molecular Weight	Approx. 4900 g/mol
Target Receptors	GLP-1R, GIPR, GcgR
Half-life	Approx. 6 days (human data)

Stability Information

Storage Requirements

Protect from light

Store away from moisture

Do not mix with other compounds

Lyophilized (powder) · −20°C · up to 2 years

Reconstituted · 2–8°C · up to 7 days

Sources & References

Peer-reviewed research

New England Journal of Medicine

Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes

2023 · PMID: 37356013

Rosenstock J et al.

View Source

New England Journal of Medicine

A Phase 2 Randomized Trial of Retatrutide for Obesity

2023 · PMID: 37367994

Jastreboff AM et al.

View Source

For Research Use Only

This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.